Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Klarna Stock Tumbles After Disappointing Q4 Results

Klarna reports unexpected losses, impacting stock performance and investor sentiment.Highlights: Klarna's stock falls sharply after reporting unexpected Q4...

FBI Warns of Surge in ATM Jackpotting Attacks

Recent spike in ATM jackpotting poses risks to financial institutions and customers.Highlights: FBI reports increased ATM jackpotting incidents...

Nvidia Considers $30 Million Investment in OpenAI

Potential investment highlights Nvidia's strategic focus on AI innovation.Highlights: Nvidia is considering a $30 million investment in OpenAI.This...

Forbes Fintech 50 Sees 20 Newcomers Strengthening Financial Inclusion

New entrants highlight AI and innovative business models in fintech.Highlights: Forbes Fintech 50 adds 20 new companies to...